title: Multiple recombinant adeno-associated viral vector serotypes display persistent in vivo gene expression in vector-transduced rat stifle joints.
abstract: Our aim was to investigate serotype-specific cell and tissue-transduction tropisms, transgene expression levels and longevity, and immunogenicity of candidate rAAV serotypes in rat osteochondral cells, tissues, and stifle joints. In vitro, we used six rAAV serotypes and two promoters to transduce synoviocytes and chondrocytes. Serotypes rAAV2/5 and 2/2 yielded the highest transduction efficiency 4 days after transduction. No differences were detected between cytomegalovirus and chicken β-actin promoters. In vivo, intra-articular injection was used to introduce four rAAV serotypes into 4-month-old rats in the left stifle joint. Eleven months later, serotype 2/5 vector, diluted with saline or surfactant, was injected into the right stifle joint of the same rats. Rats were analyzed up to 12 months after initial injection. Bioluminescence was detected at 7 days and all serotypes tested displayed bioluminescence above controls after 1 year in the left stifle. Gene expression was detected in the right stifle joints of all rats with the exception of rats previously injected with serotype 2/5. We observed no difference irrespective of whether the luciferin was injected subcutaneously or intraperitoneally. However, surfactant-diluted vectors led to increased gene expression compared with saline-diluted vectors. Cell- and tissue-specific transduction was observed in rat stifles injected with an nLacZ-containing rAAV. Transduction was greatest in stromal tissues and mesenchymal cell types. Exposure to a specific serotype did not inhibit subsequent transduction with a different serotype at a second vector injection. Including surfactant as a vector diluent increased gene expression within the stifle joint and should be considered for in vivo gene therapy applications.
authors: Department of Clinical Studies, New Bolton Center, School of Veterinary Medicine, University of Pennsylvania, Kennett Square, PA 19348-1692, USA. masonjef@vet.upenn.edu
authors: Jeffrey B
authors: JB
authors: Mason
authors: Brittney L
authors: BL
authors: Gurda
authors: Julie B
authors: JB
authors: Engiles
authors: Kurt D
authors: KD
authors: Hankenson
authors: James M
authors: JM
authors: Wilson
authors: Dean W
authors: DW
authors: Richardson
mesh_terms: D000818:Animals; D000229:Dependovirus / Q000235:genetics*; D015870:Gene Expression / Q000187:drug effects; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics / Q000378:metabolism*; D008156:Luciferases / Q000235:genetics / Q000378:metabolism; D008297:Male; D011401:Promoter Regions, Genetic; D051381:Rats; D017207:Rats, Sprague-Dawley; D012703:Serotyping; D013264:Stifle / Q000378:metabolism* / Q000473:pathology; D013501:Surface-Active Agents / Q000737:chemistry / Q000494:pharmacology; D014161:Transduction, Genetic
chemical_list: D013501:Surface-Active Agents; D008156:Luciferases
references: J Virol. 1998 Mar;72(3):2224-32
references: 9499080
references: Hum Gene Ther. 2001 Jan 1;12(1):71-6
references: 11177544
references: Mol Ther. 2011 Jun;19(6):1079-89
references: 21364543
references: Am J Vet Res. 2012 Aug;73(8):1178-85
references: 22849678
references: Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11854-9
references: 12192090
references: J Virol. 2001 Jul;75(13):6199-203
references: 11390622
references: Hum Gene Ther. 2011 Nov;22(11):1379-88
references: 21453126
references: Wound Repair Regen. 2012 Jul-Aug;20(4):592-600
references: 22713157
references: Int J Biomed Imaging. 2010;2010:471408
references: 20671955
references: J Rheumatol. 2000 Apr;27(4):983-9
references: 10782827
references: J Virol. 2007 Oct;81(20):11372-80
references: 17699581
references: J Gene Med. 2006 Aug;8(8):1027-36
references: 16733831
references: Adv Drug Deliv Rev. 2006 Jul 7;58(4):592-603
references: 16766079
references: Arch Intern Med. 2004 Jun 28;164(12):1299-304
references: 15226163
references: J Clin Immunol. 2004 Mar;24(2):162-9
references: 15024183
references: Mol Ther. 2008 Jun;16(6):1073-80
references: 18414476
references: Nat Med. 2006 Mar;12(3):342-7
references: 16474400
references: BMJ. 2000 Oct 14;321(7266):936-40
references: 11030685
references: Curr Gene Ther. 2003 Dec;3(6):545-65
references: 14683451
references: Gene Ther. 2011 Feb;18(2):128-34
references: 20844567
references: Hum Gene Ther. 2010 Jun;21(6):704-12
references: 20095819
references: Growth Factors. 1990;2(2-3):179-88
references: 2187494
references: Eur J Nucl Med Mol Imaging. 2009 May;36(5):771-9
references: 19096841
references: Mol Ther. 2007 Jun;15(6):1114-20
references: 17440444
references: Clin Rheumatol. 1992 Mar;11(1):41-7
references: 1582117
references: Mol Ther. 2008 Mar;16(3):458-65
references: 18209734
references: J Thromb Haemost. 2011 Oct;9(10):2009-19
references: 21883883
references: Mol Ther. 2011 Jun;19(6):1070-8
references: 21364538
references: Gene Ther. 1994 Jan;1(1):64-9
references: 7584062
references: Mol Ther. 2011 Nov;19(11):1961-70
references: 21730973
references: J Clin Invest. 2011 Jun;121(6):2427-35
references: 21576824
references: Mol Ther. 2009 Feb;17(2):352-9
references: 19066602
references: J Mol Med (Berl). 2008 Sep;86(9):987-97
references: 18548221
references: Exp Clin Transplant. 2009 Sep;7(3):184-7
references: 19715530
references: Osteoarthritis Cartilage. 2011 Aug;19(8):1058-65
references: 21571082
references: Adv Drug Deliv Rev. 2006 May 20;58(2):243-58
references: 16563557
references: J Virol. 1999 Apr;73(4):3410-7
references: 10074195
references: Gene Ther. 2011 Nov;18(11):1034-42
references: 21512507
references: FASEB J. 2011 Oct;25(10):3505-18
references: 21746868
references: BMJ. 2006 Mar 18;332(7542):639-42
references: 16543327